Ensysce Biosciences Files 8-K

Ticker: ENSCW · Form: 8-K · Filed: May 28, 2024 · CIK: 1716947

Ensysce Biosciences, INC. 8-K Filing Summary
FieldDetail
CompanyEnsysce Biosciences, INC. (ENSCW)
Form Type8-K
Filed DateMay 28, 2024
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

Ensysce Biosciences filed an 8-K, check for updates.

AI Summary

Ensysce Biosciences, Inc. filed an 8-K on May 28, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Leisure Acquisition Corp., is incorporated in Delaware and headquartered in La Jolla, California. This filing does not contain specific financial details or event descriptions beyond its classification.

Why It Matters

This 8-K filing indicates that Ensysce Biosciences, Inc. has submitted a report to the SEC, which may contain important updates or disclosures for investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not disclose specific material events or financial figures that would immediately indicate high risk.

Key Players & Entities

FAQ

What specific events are being reported in this 8-K filing?

The filing categorizes the reported items as 'Other Events' and 'Financial Statements and Exhibits' but does not detail the specific nature of these events within the provided text.

When was Ensysce Biosciences, Inc. incorporated?

Ensysce Biosciences, Inc. was incorporated in Delaware.

What is the principal executive office address for Ensysce Biosciences, Inc.?

The principal executive offices are located at 7946 Ivanhoe Avenue, Suite 201, La Jolla, California 92037.

What was the former name of Ensysce Biosciences, Inc.?

The former name of the company was Leisure Acquisition Corp.

What is the SEC file number for Ensysce Biosciences, Inc.?

The SEC file number for Ensysce Biosciences, Inc. is 001-38306.

Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 11.4 · Accepted 2024-05-28 08:10:33

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 28, 2024 Ensysce Biosciences, Inc. By: /s/ Lynn Kirkpatrick Name: Dr. Lynn Kirkpatrick Title: President and Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing